Background: A deregulated CRLF2 (d-CRLF2) expression was described in B-cell acute lymphoblastic leukemia without recurrent fusion genes (B-NEG ALL). While the role of d-CRLF2 in children has been extensively described, little is known about its role and impact in adult ALL. Methods: Expression levels of CRLF2 were evaluated by quantitative real-time PCR in 102 newly-diagnosed adult B-NEG ALL and correlated with the clinico-biological characteristics and outcome. Incidence and clinical impact of the P2RY8/CRLF2 transcript was also assessed. Results: High CRLF2 levels, as continuous variable, were significantly associated with hyperleucocytosis (p = 0.0002) and thrombocytopenia (p = 0.005); when a cut-point at Delta Ct <= 8 was applied, 35 cases (34.3%), mostly males (80%), proved positive for CRLF2 expression. High CRLF2 levels, as continuous or categorical variable, were associated with a worse disease -free (p = 0.003 and p = 0.015) and overall survival (p = 0.017 and 0.0038). Furthermore, when CRLF2 was analyzed as a categorical variable, a high statistical association was found with IKZFI deletion and mutations in the JAK/STAT pathway (p = 0.001 and p < 0.0001, respectively). Finally, the P2RY8/CRLF2 transcript, identified in 8/102 patients (7.8%), was associated with a poor outcome. Conclusions: In adult B-NEG ALL, high CRLF2 expression is associated with distinct clinico-biological features and an unfavourable prognosis in both univariate and multivariate analysis; similarly, P2RY8/CRLF2 positivity correlates with a poor outcome. The quantification of CRLF2 is an important prognostic marker in adult B-lineage ALL without known genetic lesions.
CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities / Chiaretti, S., Brugnoletti, F., Messina, M., Paoloni, F., Fedullo, A.L., Piciocchi, A., Elia, L., Vitale, A., Mauro, E., Ferrara, F., De Fabritiis, P., Luppi, M., Ronco, F., De Propris, M.S., Raponi, S., Kronnie, G.t., Vignetti, M., Guarini, A., Foa, R.. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - 41:(2016), pp. 36-42. [10.1016/j.leukres.2015.11.018]
CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities
CHIARETTI, sabina;PICIOCCHI, ALFONSO;ELIA, LOREDANA;VIGNETTI, Marco;GUARINI, Anna;FOA, Roberto
2016
Abstract
Background: A deregulated CRLF2 (d-CRLF2) expression was described in B-cell acute lymphoblastic leukemia without recurrent fusion genes (B-NEG ALL). While the role of d-CRLF2 in children has been extensively described, little is known about its role and impact in adult ALL. Methods: Expression levels of CRLF2 were evaluated by quantitative real-time PCR in 102 newly-diagnosed adult B-NEG ALL and correlated with the clinico-biological characteristics and outcome. Incidence and clinical impact of the P2RY8/CRLF2 transcript was also assessed. Results: High CRLF2 levels, as continuous variable, were significantly associated with hyperleucocytosis (p = 0.0002) and thrombocytopenia (p = 0.005); when a cut-point at Delta Ct <= 8 was applied, 35 cases (34.3%), mostly males (80%), proved positive for CRLF2 expression. High CRLF2 levels, as continuous or categorical variable, were associated with a worse disease -free (p = 0.003 and p = 0.015) and overall survival (p = 0.017 and 0.0038). Furthermore, when CRLF2 was analyzed as a categorical variable, a high statistical association was found with IKZFI deletion and mutations in the JAK/STAT pathway (p = 0.001 and p < 0.0001, respectively). Finally, the P2RY8/CRLF2 transcript, identified in 8/102 patients (7.8%), was associated with a poor outcome. Conclusions: In adult B-NEG ALL, high CRLF2 expression is associated with distinct clinico-biological features and an unfavourable prognosis in both univariate and multivariate analysis; similarly, P2RY8/CRLF2 positivity correlates with a poor outcome. The quantification of CRLF2 is an important prognostic marker in adult B-lineage ALL without known genetic lesions.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


